Abstract
Fresh Frozen Plasma (FFP) is prepared in blood banks throughout the world, as a separation product of whole blood. The viral safety of FFP depends on donor selection and screening. Despite implementation of measures a definite residual risk of virus transmission still remains. Estimates of residual risk vary, and depend upon the prevalence of infection within the country, the stability of the donor population and the sensitivity and specificity of the test kits used.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Piquet Y, Janvier G, Selosse P, et al. In: Smit Sibinga CTh, Das PC, Cash JD (eds). Transfusion Medicine: Fact and Fiction. Kluwer Academic Publ., Dordrecht/Boston/ London, 1991:189–90.
Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/ Detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826–31.
Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture and in vitro characterization of a sol vent/detergent-treated human plasma. Vox Sang 1992;63:178–85.
Piquet Y, Janvier G, Selosse P, et al. Virus inactivation of fresh frozen plasma by a solvent detergent procedure: Biological results. Vox Sang 1992;63:251–6.
Hellstern P, Larbig E, Walz GA, Thüringen W, Oberfrank K. Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients. Infusionstherapie und Transfusionsmedizin, S. Karger 1993;20(Suppl 2): 16–8.
Inbal A, Epstein O, Blickstein D, Kornbrot N, Brenner B, Martinowitz U. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagulation and Fibrinolysis 1993;4:599–604.
Tocci LJ, Napychank PA, Cable RG, Snyder EL. The effect of solvent/detergenttreated plasma on stored platelet concentrates. Transfusion 1993;33:145–9.
Solheim BG, Mohre B, Noddeland H, et al. The use of Octaplas in patients undergoing open heart surgery. Submitted.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Kerner, B., Selosse, P. (1994). A Plant for the Manufacturing of Virus Inactivated Plasma According to GMP-Guidelines. In: Sibinga, C.T.S., Das, P.C., Heiniger, H.J. (eds) Good Manufacturing Practice in Transfusion Medicine. Developments in Hematology and Immunology, vol 29. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2608-7_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2608-7_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6117-6
Online ISBN: 978-1-4615-2608-7
eBook Packages: Springer Book Archive